For the life sciences sector, the planned improvements in access to venture capital and in spin-offs from research institutions are of particular significance. Deep tech and biotechnology are among the technology sectors that are to be specifically strengthened. The Deutschlandfonds is intended to mobilise additional investment, whilst the High-Tech Gründerfonds and other support instruments are to be expanded. At the same time, start-up processes are to be digitised and regulatory hurdles reduced. Another focus is on the growth phase of young companies. The strategy aims to tap into more institutional capital for venture capital and to facilitate access to public procurement contracts. Cross-border expansion within Europe is also set to become easier. With this package of measures, the Federal Government is responding to increasing international competition for technologies, capital and talent. For companies in the biotechnology, medical technology and digital health sectors, the strategy could help to accelerate the transfer of scientific findings into marketable products and improve the long-term financing of high-growth companies.
News from the “Federal Government” dated 22 July 2026